×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BBIO – bridgebio pharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BBIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
02:49 pm
bbio
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market [Yahoo! Finance]
Low
Report
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market [Yahoo! Finance]
11/19
06:25 am
bbio
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically [Yahoo! Finance]
Low
Report
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically [Yahoo! Finance]
11/18
11:28 am
bbio
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months [Yahoo! Finance]
Medium
Report
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months [Yahoo! Finance]
11/18
11:15 am
bbio
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Low
Report
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
11/18
05:31 am
bbio
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia [Yahoo! Finance]
11/18
05:30 am
bbio
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
Medium
Report
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
11/15
12:19 pm
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $44.00 to $45.00. They now have a "sector outperform" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $44.00 to $45.00. They now have a "sector outperform" rating on the stock.
11/14
05:32 am
bbio
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
08:01 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Nov 19 Filed by: Kumar Neil
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Nov 19 Filed by: Kumar Neil
11/20
07:58 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Nov 19 Filed by: STEPHENSON BRIAN C
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Nov 19 Filed by: STEPHENSON BRIAN C
11/19
06:16 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: Kumar Neil
Medium
Report
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: Kumar Neil
11/19
06:14 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: Trimarchi Thomas
Medium
Report
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: Trimarchi Thomas
11/19
06:06 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: STEPHENSON BRIAN C
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: STEPHENSON BRIAN C
11/19
04:29 pm
bbio
Form 144 BridgeBio Pharma, Inc. Filed by: STEPHENSON BRIAN C
Low
Report
Form 144 BridgeBio Pharma, Inc. Filed by: STEPHENSON BRIAN C
11/19
04:25 pm
bbio
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
Low
Report
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
11/12
11:45 am
bbio
Form SC 13G/A BridgeBio Pharma, Inc. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A BridgeBio Pharma, Inc. Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
BridgeBio Pharma (NASDAQ: BBIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
26.9%
12/19 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference 13.7%
4/3 Form 4 BridgeBio Pharma, Inc. For: Apr 01 Filed by: STEPHENSON BRIAN C 12.4%
10/30 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
11/7 Q3/2019 9/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%
7/22 BridgeBio Pharma (NASDAQ: BBIO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 10.3%
4/7 Form 4 BridgeBio Pharma, Inc. For: Apr 03 Filed by: HOMCY CHARLES J 10.3%
12/9 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs 10.2%
12/18 BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A 10.1%
11/19 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
12/19 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference 13.7%
4/3 Form 4 BridgeBio Pharma, Inc. For: Apr 01 Filed by: STEPHENSON BRIAN C 12.4%
10/30 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
11/7 Q3/2019 9/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%
7/22 BridgeBio Pharma (NASDAQ: BBIO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 10.3%
4/7 Form 4 BridgeBio Pharma, Inc. For: Apr 03 Filed by: HOMCY CHARLES J 10.3%
12/9 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs 10.2%
12/18 BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A 10.1%
11/19 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
TOP News Decliners
3/12
BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations
-16.6%
12/26 Form 8-K BridgeBio Pharma, Inc. For: Nov 07 -14.3%
6/26 Form S-1MEF BridgeBio Pharma, Inc. -10.0%
2/21 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences -8.0%
9/24 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options -7.8%
1/10 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity -7.6%
4/7 Form SEC STAFF LETTER BridgeBio Pharma, Inc. -5.8%
12/24 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.5%
12/31 Form 4 BridgeBio Pharma, Inc. For: Dec 27 Filed by: MCCORMICK FRANK -5.2%
3/3 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) -4.7%
12/26 Form 8-K BridgeBio Pharma, Inc. For: Nov 07 -14.3%
6/26 Form S-1MEF BridgeBio Pharma, Inc. -10.0%
2/21 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences -8.0%
9/24 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options -7.8%
1/10 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity -7.6%
4/7 Form SEC STAFF LETTER BridgeBio Pharma, Inc. -5.8%
12/24 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.5%
12/31 Form 4 BridgeBio Pharma, Inc. For: Dec 27 Filed by: MCCORMICK FRANK -5.2%
3/3 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: